Wave Life Sciences announced positive Phase 1b/2a trial results for WVE-006, an RNA editing therapy for alpha-1 antitrypsin deficiency (AATD). The treatment effectively restored protective M-AAT protein levels and reduced harmful Z-AAT protein in patients, mimicking a low-risk MZ-like phenotype with both biweekly and monthly dosing. WVE-006 also demonstrated a strong safety profile and sustained effects for at least three months post-treatment. The company expects FDA feedback on accelerated approval by mid-2026 and plans to share further data later this year.
Visa Canada has inaugurated a street soccer park at Nathan Phillips Square in Toronto, contributing CA$200,000 to the city's Soccer for All Legacy program. This temporary park, open until July 19, features two professional-grade mini-fields and local...
Target is set to report its fiscal first-quarter earnings as CEO Michael Fiddelke leads a turnaround effort amid ongoing sales slumps and consumer uncertainty due to rising gas prices and economic concerns. Analysts expect earnings per share of $1.46...
Arteris, Inc. announced its system IP technology is adopted by Li Auto for its new L9 Livis flagship SUV, integrating the Mach M100 autonomous driving SoC. This collaboration enhances AI data movement and system efficiency, meeting high performance, ...
Li Auto has integrated Arteris' FlexNoC 5 network-on-chip IP and Magillem software into its proprietary autonomous driving SoCs for the new L9 Livis SUV. This technology supports AI data movement and integration, enabling the vehicle to perform 2,560...
The JPMorgan Equity Premium Income ETF (JEPI) has been upgraded to Buy following recent price weakness and an attractive yield range of 7-8%. The ETF’s high monthly payouts were driven by recent market volatility, but distributions are expected to de...
